HSS Journal

, Volume 2, Issue 2, pp 141–147 | Cite as

Perioperative Management of Medications Used in the Treatment of Rheumatoid Arthritis

  • Carla R. Scanzello
  • Mark P. Figgie
  • Bryan J. Nestor
  • Susan M. Goodman
Article

Abstract

Patients with rheumatoid arthritis (RA), an inflammatory arthritis that can destroy joint structures, are often on multiple medications to control disease activity. These medications may have significant toxicities and side effects. Over the course of their lifetime, patients with this disease often require orthopedic procedures, including total joint arthroplasty, and the medications they are taking present management issues specific to the perioperative period. As many of these medications are immunosuppressive, the concern for postoperative infection and delayed wound healing are particularly worrisome. We conducted a review of the available literature pertaining to the perioperative use of the most commonly prescribed medications for RA. Although the existing data directly addressing perioperative complications in orthopedic surgery is sparse, information on relevant complications resulting from the general use of these drugs may be used as a basis for conservative recommendations.

Key words

Rheumatoid arthritis perioperative management corticosteroids methotrexate anti-TNF rituximab 

References

  1. 1.
    An YH, Friedman RJ (1996) Prevention of sepsis in total joint arthroplasty. J Hosp Infect 33:93–108PubMedCrossRefGoogle Scholar
  2. 2.
    Schlaghecke R, Kornely E, Santen RT, Ridderskamp P (1992) The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 326:226–230PubMedCrossRefGoogle Scholar
  3. 3.
    McPhee IB, Williams RP, Swanson CE (1998) Factors influencing wound healing after surgery for metastatic disease of the spine. Spine 23:726–732PubMedCrossRefGoogle Scholar
  4. 4.
    Busti AJ, Hooper JS, Amaya CJ, Kazi S (2005) Effects of perioperative anti-inflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy 25:1566–1591PubMedCrossRefGoogle Scholar
  5. 5.
    Mathis AS, Shah NK, Mulgaonkar S (2004) Stress dose steroids in renal transplant patients undergoing lymphocele surgery. Transplant Proc 36:3042–3045PubMedCrossRefGoogle Scholar
  6. 6.
    Bromberg JS, Alfrey EJ, Barker CF, et al (1991) Adrenal suppression and steroid supplementation in renal transplant recipients. Transplantation 51:385–390PubMedCrossRefGoogle Scholar
  7. 7.
    Glowniak JV, Loriaux DL (1997) A double-blind study of perioperative steroid requirements in secondary adrenal insufficiency. Surgery 121:123–129PubMedCrossRefGoogle Scholar
  8. 8.
    Leopold SS, Casnellie MT, Warme WJ, et al (2003) Endogenous cortisol production in response to knee arthroscopy and total knee arthroplasty. J Bone Jt Surg Am Vol 85-A:2163–2167Google Scholar
  9. 9.
    Bruewer M, Utech M, Rijcken EJ, et al (2003) Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohns disease. World J Surg 27:1306–1310PubMedCrossRefGoogle Scholar
  10. 10.
    Aberra FN, Lewis JD, Hass D, et al (2003) Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 125:320–327PubMedCrossRefGoogle Scholar
  11. 11.
    Jain A, Witbreuk M, Ball C, Nanchahal J (2002) Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg [Am] 27:449–455CrossRefGoogle Scholar
  12. 12.
    Hanssen AD, Cabanela ME, Michet CJ Jr (1987) Hip arthroplasty in patients with systemic lupus erythematosus. J Bone Jt Surg Am Vol 69:807–814Google Scholar
  13. 13.
    Levitsky J, Te HS, Cohen SM (2003) The safety and outcome of joint replacement surgery in liver transplant recipients. Liver Transplant 9:373–376CrossRefGoogle Scholar
  14. 14.
    Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57:163–172PubMedCrossRefGoogle Scholar
  15. 15.
    Choi HK, Hernan MA, Seeger JD, et al (2002) Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359:1173–1177PubMedCrossRefGoogle Scholar
  16. 16.
    Pincus T, Yazici Y, Sokka T, et al (2003) Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21:S179–S185PubMedGoogle Scholar
  17. 17.
    Grennan DM, Gray J, Loudon J, Fear S (2001) Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 60:214–217PubMedCrossRefGoogle Scholar
  18. 18.
    Sany J, Anaya JM, Canovas F et al (1993) Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 20:1129–1132PubMedGoogle Scholar
  19. 19.
    Carpenter MT, West SG, Vogelgesang SA, Casey Jones DE (1996) Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics 19:207–210PubMedGoogle Scholar
  20. 20.
    Bibbo C, Anderson RB, Davis WH, Norton J (2003) The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients. Foot Ankle Int 24:40–44PubMedGoogle Scholar
  21. 21.
    Bland KI, Palin WE, von Fraunhofer JA et al (1984) Experimental and clinical observations of the effects of cytotoxic chemotherapeutic drugs on wound healing. Ann Surg 199:782–790PubMedCrossRefGoogle Scholar
  22. 22.
    Cohen SC, Gabelnick HL, Johnson RK, Goldin A (1975) Effects of antineoplastic agents on wound healing in mice. Surgery 78:238–244PubMedGoogle Scholar
  23. 23.
    Hernigou P, Thiery JP, Benoit J et al (1989) Methotrexate diffusion from acrylic cement. Local chemotherapy for bone tumours. J Bone Jt Surg Br 71:804–811Google Scholar
  24. 24.
    Shamberger RC, Devereux DF, Brennan MF (1981) The effect of chemotherapeutic agents on wound healing. Int Adv Surg Oncol 4:15–58PubMedGoogle Scholar
  25. 25.
    Kasdan ML, June L (1993) Postoperative results of rheumatoid arthritis patients on methotrexate at the time of reconstructive surgery of the hand. Orthopedics 16:1233–1235PubMedGoogle Scholar
  26. 26.
    Lim V, Pande I (2002) Leflunomide can potentiate the anticoagulant effect of warfarin. BMJ 325:1333PubMedCrossRefGoogle Scholar
  27. 27.
    Feldmann MM, Maini RN (2002) Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint, Bone, Spine 69:12–18PubMedCrossRefGoogle Scholar
  28. 28.
    Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH (2003) Comparison of the efficacy of the tumour necrosis factor α blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 62(Suppl 2):ii13–ii16PubMedGoogle Scholar
  29. 29.
    Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. NEJM 343:1594–1602PubMedCrossRefGoogle Scholar
  30. 30.
    Hyrich KL, Silman AJ, Watson KD, Symmons DP (2004) Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63:1538–1543PubMedCrossRefGoogle Scholar
  31. 31.
    Fisher CJ, Agosti JM, Opal SM et al (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. NEJM 334:1697–1702PubMedCrossRefGoogle Scholar
  32. 32.
    Marchal L, D'Haens G, Van Assche G et al (2004) The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 19:749–754PubMedCrossRefGoogle Scholar
  33. 33.
    Colombel JF, Loftus EV Jr, Tremaine WJ et al (2004) Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99:878–883PubMedCrossRefGoogle Scholar
  34. 34.
    Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25:331–335PubMedGoogle Scholar
  35. 35.
    Giles JT, Bartlett SJ, Gelber AC, et al (2006) Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in Rheumatoid Arthritis. Arthritis Care Res 55:333–337CrossRefGoogle Scholar
  36. 36.
    Kawaguchi HH, Hizuta AA, Tanaka NN, Orita KK (1995) Role of endotoxin in wound healing impairment. Res Commun Mol Pathol Pharmacol 89:317–327PubMedGoogle Scholar
  37. 37.
    Doran MF, Crowson CS, Pond GR, et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293PubMedCrossRefGoogle Scholar
  38. 38.
    Edwards JC, Szczepanski L, Szechinski J, et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. NEJM 350:2572–2581PubMedCrossRefGoogle Scholar
  39. 39.
    White CA, Weaver RL, Grillo-Lopez AJ (2001) Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 52:125–145PubMedCrossRefGoogle Scholar
  40. 40.
    Sarrecchia C, Cappelli A, Aiello P (2005) HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 11:189–191PubMedCrossRefGoogle Scholar
  41. 41.
    Law JK, Ho JK, Hoskins PJ, et al (2005) Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 46:1085–1089PubMedCrossRefGoogle Scholar
  42. 42.
    Tsutsumi Y, Kanamori H, Mori A, et al (2005) Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Safety 4:599–608CrossRefGoogle Scholar
  43. 43.
    Cambridge G, Leandro MJ, Edwards JC, et al (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:2146–2154PubMedCrossRefGoogle Scholar

Copyright information

© Hospital for Special Surgery 2006

Authors and Affiliations

  • Carla R. Scanzello
    • 1
  • Mark P. Figgie
    • 2
  • Bryan J. Nestor
    • 2
  • Susan M. Goodman
    • 1
  1. 1.Department of RheumatologyHospital for Special SurgeryNew YorkUSA
  2. 2.Department of Orthopedic SurgeryHospital for Special SurgeryNew YorkUSA

Personalised recommendations